Energy News / Shareholders Foundation, Inc.

NASDAQ:SRPT Shareholder Notice: Investigation over Possible Securities Laws Violations by Sarepta Therapeutics, Inc.

Via: ReleaseWire

Updated 12:00 PM CDT, Mon, September 16,2019

An investigation for investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares over potential securities laws violations by Sarepta Therapeutics, Inc. was announced.

San Diego, CA -- (SBWIRE) -- 09/16/2019 -- An investigation was announced on behalf of investors in NASDAQ: SRPT shares concerning possible securities laws violations by Sarepta Therapeutics, Inc. in connection with certain financial statements.

Investors who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Sarepta Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. On August 19, 2019, Sarepta Therapeutics, Inc. announced receipt of a Complete Response Letter ("CRL") from the U.S. Food & Drug Administration regarding the Company's New Drug Application seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy. Sarepta disclosed that "[t]he CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides." Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) declined to as low as $90.24 per share on August 22, 2019.

Those who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in conftact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqsrpt-shareholder-notice-investigation-over-possible-securities-laws-violations-by-sarepta-therapeutics-inc-1259762.htm

Media Relations Contact
Michael Daniels
1-858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com